Cargando…
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Despite extensive research, no disease-modifying therapeutic option, able to prevent, cure or halt the progression of Alzheimer’s disease [AD], is currently available. AD, a devastating neurodegenerative pathology leading to dementia and death, is characterized by two pathological hallmarks, the ext...
Autores principales: | Melchiorri, Daniela, Merlo, Sara, Micallef, Benjamin, Borg, John-Joseph, Dráfi, František |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272781/ https://www.ncbi.nlm.nih.gov/pubmed/37332353 http://dx.doi.org/10.3389/fphar.2023.1196413 |
Ejemplares similares
-
Editorial: Pharmacology of autoimmune and neuroinflammatory disease from a preclinical and clinical perspective
por: Šíma, Martin, et al.
Publicado: (2023) -
Metabolomics paves the way for improved drug target identification
por: Garana, Belinda B, et al.
Publicado: (2022) -
Paving the way to metastasis
por: Van Epps, Heather L.
Publicado: (2005) -
Revisiting the neuroinflammation hypothesis in Alzheimer’s disease: a focus on the druggability of current targets
por: Wong-Guerra, Maylin, et al.
Publicado: (2023) -
Paving the Way for Apollo 11
por: Harland, David M
Publicado: (2009)